INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 178 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2015. The put-call ratio across all filers is 1.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2015 | $7,602,000 | -20.6% | 45,835 | +15.5% | 0.02% | -8.0% |
| Q2 2015 | $9,576,000 | -53.1% | 39,671 | -45.2% | 0.02% | -51.9% |
| Q1 2015 | $20,426,000 | -52.2% | 72,428 | -59.9% | 0.05% | -51.4% |
| Q3 2014 | $42,720,000 | -55.9% | 180,491 | -55.9% | 0.11% | -2.7% |
| Q2 2014 | $96,846,000 | +1916.8% | 409,270 | +481.9% | 0.11% | +900.0% |
| Q4 2013 | $4,802,000 | -53.8% | 70,334 | -53.3% | 0.01% | -54.2% |
| Q3 2013 | $10,389,000 | +52.5% | 150,501 | -0.9% | 0.02% | +50.0% |
| Q2 2013 | $6,812,000 | – | 151,913 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |